EFC16035 & EFC16035 Actigraphy (PERSEUS)

EFC16035 & EFC16035 Actigraphy (PERSEUS), a biological drug for the treatment of primary progressive multiple sclerosis (PPMS)

$

This study evaluates the safety and effectiveness of the drug SAR442168 for the treatment of PPMS

$

This trial is not accepting new patients.

$

The purpose of the study is to see if the study drug, SAR442168, works to delay the progression of disability in people with PPMS compared to placebo and has an acceptable safety profile.

$

Basic Enrollment Criteria:

  • Age 18-55 years old, Male & Female
  • Willing to comply with study visits and requirements
$

Study Length:

  • approximately 4 years

Participate In This Study

Sign-up Here